Effect of a nutrient mixture on the localization of extracellular matrix proteins in HeLa human cervical cancer xenografts in female nude mice
- Authors:
- Published online on: June 23, 2015 https://doi.org/10.3892/etm.2015.2591
- Pages: 901-906
-
Copyright: © Roomi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Abstract
Introduction
Cervical cancer is the third most commonly diagnosed cancer and the fourth most common cause of mortality in women worldwide (1). In 2014, ~12,360 new cases of invasive cervical cancer and ~4,020 cases of mortality from this disease were estimated for the USA (2). The development of cervical cancer is a slow process; it typically takes 10–15 years for the pre-cancerous condition dysplasia to develop into cancer. Although cervical cancer is fully treatable in the early stages, once it has metastasized, patient outcome is poor (3).
Metastasis occurs following the detachment of cancer cells from the primary tumor. The detached cells invade through degraded basement membrane into the surrounding stroma, enter into the vascular or lymphatic system and are transported to distal sites such as the liver, lungs and brain, where they undergo extravasation, tumor cell proliferation and angiogenesis (4–8). The extracellular matrix (ECM), which comprises collagen, proteoglycans, fibronectin, laminin and other glycoproteins (9–11), acts as a barrier to cancer cell invasion, and tumor cell invasion is dependent upon its degradation. Matrix metalloproteinases (MMPs) and urokinase plasminogen activators (uPA) are also involved in tumor invasion and metastasis. Clinical and experimental studies have indicated that elevated levels of uPA and MMPs are associated with tumor growth, cancer progression, metastasis and a reduction in the survival time of patients (12,13). The expression of MMP-9 at the mRNA and protein levels has been shown to be significantly elevated in tumor and stromal cells of invasive squamous cell carcinoma of the uterine cervix (14).
Nutrients such as lysine and ascorbic acid have been suggested to target plasmin-mediated connective tissue degradation as a universal approach to the prevention of tumor growth and expansion (15). Lysine binds to the active sites of plasminogen, thereby blocking the conversion of plasminogen to plasmin and the plasmin-induced MMP activation cascade (16). We have developed a strategy to inhibit the development and spread of cancer using a nutrient mixture (NM) comprising nutrients such as lysine, proline, ascorbic acid and green tea extract. This mixture has exhibited synergistic anticancer activity in vivo and in vitro in a number of cancer cell lines through the inhibition of cancer cell growth, MMP secretion, invasion, metastasis and angiogenesis (17).
In previous studies, NM was found to significantly inhibit HeLa cervical cancer cell proliferation in vitro, MMP-2 and -9 secretion, uPA activity and Matrigel invasion, in addition to enhancing TIMP-2 activity (18,19). In the present study the in vivo effect of NM supplementation on tumor growth and ECM protein markers were investigated in HeLa cervical tumor xenografts in female nude mice. Morphological changes in key ECM proteins associated with the tumor, including collagen I, collagen IV, fibronectin, laminin, periodic acid-Schiff (PAS) and elastin, were evaluated.
Materials and methods
Animals
Female athymic nude mice, ~5 weeks of age, were purchased from Simonsen Laboratories (Gilroy, CA, USA) and maintained in microisolator cages under pathogen-free conditions on a 12-h light/12-h dark schedule for 1 week. All procedures were performed according to guidelines for the humane and customary care and use of experimental animals and followed a protocol prepared by a veterinary consultant of Stanford University (Stanford, CA, USA) and approved by the Animal Safety Review Committee of Dr Rath Research Institute (Santa Clara, CA, USA).
Experimental design
After housing for 1 week, 5- or 6-week-old female athymic nude mice (n=12) were inoculated subcutaneously with 3×106 HeLa cells in 0.2 ml phosphate-buffered saline (PBS) and 0.1 ml Matrigel (BD Biosciences, Bedford, MA, USA). Following the inoculation, the mice were randomly divided into two groups. These were the control group, in which the mice were fed regular Purina mouse chow (Laboratory Rodent Diet 5001; Purina Mills, Richmond, IN, USA), and the NM group, in which the mice were fed the regular diet supplemented with 0.5% NM (w/w). The mice consumed an average of 4 g diet/day during the study. Thus, the supplemented mice received ~20 mg NM per day. After 4 weeks, the mice were anesthetized/sacrificed by exposure to isoflurane USP soaked cotton balls (Piramel Healthcare Ltd., Medak, Ap, India) in a closed environment. The tumors were excised, weighed and processed for histological examination. The mean weight of the mice at the initiation and termination of the study did not differ significantly between the groups.
Immunohistochemistry
Tumors were placed in a formalin cassette and sent to IDEXX Laboratories, Inc. (Sacramento, CA, USA) and HistoTox Labs, Inc. (Boulder, CO, USA) for analysis. Formalin-fixed samples of tumors were trimmed, processed, blocked, sectioned and stained with hematoxylin and eosin (H&E) and elastic-Van Gieson stains, and evaluated microscopically by IDEXX Laboratories, Inc. HistoTox Labs, Inc. conducted PAS histochemistry of the tumor sections as well as the immunohistochemical analysis of collagens I and IV, fibronectin, laminin and elastin.
Results
Tumor growth
NM strongly inhibited the growth of HeLa xenografts in nude mice. In the mice that were fed a diet supplemented with 0.5% NM, the tumor weight was inhibited by 59% (P=0.001) compared with that in the control group mice, as shown in Fig. 1. No significant difference in initial and final mean body weights was observed between the groups.
Histology of the tumors
Histology of the two groups was comparable. However, the fibrous capsule in the NM-treated group was prominent while the tumor border in the untreated group was poorly defined (not shown).
Collagen I
Tumors from control mice exhibited little to no collagen I expression, either internally or in the fibrous capsule, as shown in Fig. 2A and B. By contrast, tumors from the NM-treated mice expressed notably greater expression levels of collagen I in the fibrous capsule and some interdigitation and lamellar structures of collagen I within the tumor (Fig. 2C and D).
Collagen IV
The control tumors demonstrated diffuse cytoplasmic and capsular collagen IV with abundant nucleated cells, as shown in Fig. 3A and B. There was an intense increase in collagen IV production within the tumors of the mice that underwent treatment with NM. NM supplementation induced a dense fibrous network of collagen IV, creating chambers that surrounded live nucleated cells and large amounts of necrotic cell debris, as shown in Fig. 3C and D. The fibrotic network of collagen IV became denser towards the core of the tumor and the increased density of collagen IV was associated with a greater amount of cell necrosis, as evidenced by a lack of nuclear staining.
Fibronectin
Less fibronectin appeared in the control tumor tissue than in the tumors from the NM-treated mice. Tumors from the control group exhibited intense sporadic internal staining in a heterogeneous interdigitating pattern with very little staining in the fibrous capsule (Fig. 4A and B). Tumors from the NM-treated mice exhibited a well-defined border of fibronectin in the capsule and intense areas of staining internally (Fig. 4C and D).
Laminin
Laminin appeared abundantly in the tumors from the control and NM groups. In the NM group, chamber-like networks of laminin were formed within the tumors (Fig. 5).
PAS
Tumors from the control group exhibited internal areas of intense PAS staining (Fig. 6A and B) whereas the tumors from the NM-treated group showed a more uniform and diffuse pattern of PAS staining (Fig. 6C and D).
Elastin
No conclusive difference was observed between the tumors from the control and NM-treated groups (not shown).
Discussion
Tumor cell invasion is associated with degradation of the ECM, which is intact in normal cells. Among various types of MMP, MMP-2 and MMP-9 are pivotal in tumor cell invasion and metastasis as they degrade type IV collagen, a major component of the ECM (11–13). Barsky et al demonstrated that in invasive tumors the basement membrane, specifically collagen IV and laminin components, was thinned, fragmented and disrupted, while benign and in situ lesions had intact basement membranes with linear staining of collagen IV and laminin (10). Stromal resistance to invasion is dependent upon the encapsulation of the neoplastic cells by a practically impenetrable barrier of dense fibrous tissue (15,20). In the present study, NM supplementation of HeLa xenograft-bearing female nude mice resulted in a significant reduction in mean tumor weight compared with that in the control group. Furthermore, immunohistochemical staining of the tumors confirmed the protective effect of nutrient supplementation on the basement membrane.
Control group tumors showed diffuse cytoplasmic and capsular collagen IV with abundant nucleated cells. In marked contrast, NM supplementation induced intense internal collagen IV production, forming a dense fibrous network of collagen IV that surrounded live nucleated cells and large amounts of necrotic cellular debris. The fibrotic response observed with NM supplementation is similar to the collagen deposition reported by Almholt et al when investigating an experimental pan-MMP inhibiting drug, which was shown to decrease metastatic burden 100-fold (21). Furthermore, tumors from the control group mice exhibited little to no collagen I expression either internally or in the fibrous capsule. By contrast, tumors from the NM-treated mice expressed greater amounts of collagen I in the fibrous capsule, and some interdigitation and lamellar structures of collagen I were present within the tumor.
Fibronectin, a high molecular weight glycoprotein binds ECM components such as collagen, fibrin and heparin sulfate proteoglycans (22). Fibronectin affects various cellular interactions with the ECM and plays important roles in cell adhesion, migration, growth and differentiation (23). Altered fibronectin expression, degradation and organization have been associated with cancer progression (23). Tumors from NM-treated mice exhibited well-defined borders of fibronectin in the capsule and intense areas of staining internally. By contrast, control tumors showed less fibronectin staining with a sporadic internal pattern and little in the fibrous capsule.
Laminins, major glycoproteins in the basal lamina, influence cell differentiation, migration and adhesion, as well as phenotype and survival (24). In the present study, laminin appeared abundantly in tumors from the two groups. In tumors from the NM-treated mice, chamber-like networks of laminin were formed internally.
Nutrients such as lysine and ascorbic acid have been hypothesized to modulate tumor growth and expansion by inhibiting ECM degradation and MMP activity, and strengthening the integrity of the connective tissue surrounding cancer cells (15). Based on this approach we developed a complex of nutrients that can simultaneously affect key cancer mechanisms through their synergistic effects. The individual components of this mixture have various effects on certain critical aspects of cancer. For optimization of the structure of the ECM, adequate supplies of ascorbic acid and the amino acids lysine and proline are essential to ensure the proper synthesis and hydroxylation of collagen fibers. In addition, lysine contributes to the stability of the ECM as a natural inhibitor of plasmin-induced proteolysis (15,25). Manganese and copper are essential cofactors for collagen formation. Green tea extract has a well-documented ability to modulate cancer cell growth, metastasis, angiogenesis and other aspects of cancer progression (26–30). N-acetyl cysteine and selenium have demonstrated the ability to inhibit the expression of MMP-9 and invasive activities of tumor cells, as well as the migration of endothelial cells through ECM (31–33). Ascorbic acid has demonstrated cytotoxic and antimetastatic actions on malignant cell lines (34–39), and it has been observed that the levels of ascorbic acid in cancer patients are low (40,41). Low levels of arginine, a precursor of nitric oxide (NO), can limit the production of NO, which has been shown to predominantly act as an inducer of apoptosis (42).
The results of the present study demonstrated that NM potently inhibited tumor growth and enhanced the expression of ECM proteins in female nude mice with HeLa xenografts, suggesting the therapeutic value of this specific nutrient complex in the treatment of cervical cancer. Supplementation with NM has beneficial effects in optimizing the basement membrane by increasing the stability and thickness of collagen IV, collagen I and the glycoproteins supporting the matrix, such as laminin and fibronectin. Furthermore, the micronutrient mixture appears to be safe to use. In a previous in vivo study addressing safety, it was observed that administering NM at doses of 30, 90 or 150 mg/day to adult female osteogenic disorder Shionogi (ODS) rats (weighing 250–300 g) for 7 days, had no adverse effects on vital organs (heart, liver and kidney). In addition, it did not adversely affect functional serum enzymes, indicating that the NM is safe to use even at these high doses, which far exceed the normal equivalent dosage of the nutrient (43).
Acknowledgements
This study was funded by Dr. Rath Health Foundation (Santa Clara, CA, USA), a non-profit organization. The authors would particularly like to thank Earl Rainey for maintenance of the animal colony.
References
Jemal A, Bray F, Center MM, Ferley J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI | |
American Cancer Society, . Cervical cancer: What are the key statistics about cervical cancer? http://www.cancer.org/cancer/cervicalcancer/detailedguide/cervical-cancer-key-statisticsLast revised. January 31–2014 June 9–2014 | |
Cancer.net, . Cervical cancer: Statistics. http://www.cancer.net/cancer-types/cervical-cancer/statisticsLast reviewed. April;2014 June 9–2014 | |
Fidler IJ: Molecular biology of cancer: Invasion and metastasisCancer Principles and Practice of Oncology. DeVita VT Jr, Hellman S and Rosenberg SA: 5th. Lippincott-Raven; Philadelphia, PA: pp. 135–152. 1997 | |
Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2:161–174. 2002. View Article : Google Scholar : PubMed/NCBI | |
Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 29:(Suppl 16). 15–18. 2002. View Article : Google Scholar : PubMed/NCBI | |
Chambers AF and Matrisian LM: Changing views on the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 89:1260–1270. 1997. View Article : Google Scholar : PubMed/NCBI | |
Kleiner DE and Stetler-Stevenson WG: Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol. 43:(Suppl). 42–51. 1999. View Article : Google Scholar | |
Yurchenko PD and Schitny JC: Molecular architecture of basement membranes. FASEB J. 4:1577–1590. 1990.PubMed/NCBI | |
Barsky SH, Siegel GP, Jannotta F and Liotta LA: Loss of basement membrane components by invasive tumors but not by their benign counterparts. Lab Invest. 49:140–147. 1983.PubMed/NCBI | |
Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM and Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 284:67–68. 1980. View Article : Google Scholar : PubMed/NCBI | |
Stetler-Stevenson WG: The role of matrix metalloproteinases in tumor invasion, metastasis and angiogenesis. Surg Oncol Clin N Am. 10:383–392. 2001.PubMed/NCBI | |
Stetler-Stevenson WG: Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev. 9:289–303. 1990. View Article : Google Scholar : PubMed/NCBI | |
Davidson B, Goldberg I, Koplovic J, Lerner-Geva L, Gottlieb WH, Weiss B, Ben-Baruch G and Reich R: Expression of matrix metalloproteinase-9 in squamous cell carcinoma of the uterine cervix - clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol. 72:380–386. 1999. View Article : Google Scholar : PubMed/NCBI | |
Rath M and Pauling L: Plasmin-induced proteolysis and the role of apoprotein (a), lysine and synthetic analogs. J Orthomol Med. 7:17–23. 1992. | |
Andreasen PA, Kjøller L, Christensen L and Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer. 72:1–22. 1997. View Article : Google Scholar : PubMed/NCBI | |
Niedzwiecki A, Roomi MW, Kalinovsky T and Rath M: Micronutrient synergy - a new tool in effective control of metastasis and other key mechanisms of cancer. Cancer Metastasis Rev. 29:529–543. 2010. View Article : Google Scholar : PubMed/NCBI | |
Roomi MW, Kalinovsky T, Rath M and Niedzwiecki A: Modulation of u-PA, MMPs and their inhibitors by a novel nutrient mixture in human female cancer cell lines. Oncol Rep. 28:768–776. 2012.PubMed/NCBI | |
Roomi MW, Ivanov V, Kalinovsky T, Niedzwiecki A and Rath M: Suppression of human cervical cancer cell lines Hela and DoTc2 4510 by a mixture of lysine, proline, ascorbic acid and green tea extract. Int J Gynecol Cancer. 16:1241–1247. 2006. View Article : Google Scholar : PubMed/NCBI | |
Cameron E, Pauling L and Leibovitz B: Ascorbic acid and cancer: A review. Cancer Res. 39:663–681. 1979.PubMed/NCBI | |
Almholt K, Juncker-Jensen A, Laerum OD, Danø K, Johnsen M, Lund LR and Rømer J: Metastasis is strongly reduced by the matrix metalloproteinase inhibitor Galardin in the MMTV-PymT transgenic breast cancer model. Mol Cancer Ther. 7:2758–2767. 2008. View Article : Google Scholar : PubMed/NCBI | |
Pankov R and Yamada KM: Fibronectin at a glance. J Cell Sci. 115:3861–3863. 2002. View Article : Google Scholar : PubMed/NCBI | |
Ruoslahti E: Fibronectin and its integrin receptors in cancer. Adv Cancer Res. 76:1–20. 1999. View Article : Google Scholar : PubMed/NCBI | |
Timpl R, Rohde H, Robey PG, Rennard SI, Foidart JM and Martin GR: Laminin - a glycoprotein from basement membranes. J Biol Chem. 254:9933–9937. 1979.PubMed/NCBI | |
Sun Z, Chen YH, Wang P, Zhang J, Gurewich V, Zhang P and Liu JN: The blockage of high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation. Biochem Biophys Acta. 1596:182–192. 2002.PubMed/NCBI | |
Valcic S, Timmermann BN, Alberts DS, Wachter GA, Krutzsch M, Wymer J and Guillén JM: Inhibitory effect of six green tea catechins and caffeine on the growth of four selected human tumor cell lines. Anticancer Drugs. 7:461–468. 1996. View Article : Google Scholar : PubMed/NCBI | |
Mukhtar H and Ahmed N: Tea polyphenols: Prevention of cancer and optimizing health. Am J Clin Nutr. 71:(Sul 6). 1698S–1702S. 2000.PubMed/NCBI | |
Yang CY, Liao J, Kim K, Yurtow EJ and Yang CS: Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis. 19:611–616. 1998. View Article : Google Scholar : PubMed/NCBI | |
Taniguchi S, Fujiki H, Kobayashi H, Go H, Miyado K, Sadano H and Shimikawa R: Effect of (−) epigallocatechin gallate, the main constituent of green tea, on lung metastasis with mouse B16 melanoma cell lines. Cancer Lett. 65:51–54. 1992. View Article : Google Scholar : PubMed/NCBI | |
Hara Y: Green Tea - Health Benefits and Applications. Marcel Dekker; New York, NY: 2001, View Article : Google Scholar | |
Kawakami S, Kageyama Y, Fujii Y, Kihara K and Oshima H: Inhibitory effects of N-acetyl cysteine on invasion and MMP-9 production of T24 human bladder cancer cells. Anticancer Res. 21:213–219. 2001.PubMed/NCBI | |
Morini M, Cai T, Aluigi MG, Noonan DM, Masiello L, De Floro S, D'Agostinin F, Albini A and Fassima G: The role of the thiol N-acetyl cysteine in the prevention of tumor invasion and angiogenesis. Int J Biol Markers. 14:268–271. 1999.PubMed/NCBI | |
Yoon SO, Kim MM and Chung AS: Inhibitory effects of selenite on invasion of HT 1080 tumor cells. J Biol Chem. 276:20085–20092. 2001. View Article : Google Scholar : PubMed/NCBI | |
Cha J, Roomi MW, Ivanov V, Kalinovsky T, Niedzwiecki A and Rath M: Ascorbate supplementation inhibits growth and metastasis of B16FO melanoma and 4T1 breast cancer cells in vitamin C deficient mice. Int J Oncol. 42:55–64. 2013.PubMed/NCBI | |
Naidu KA, Karl RC, Naidu KA and Coppola D: Antiproliferative and proapoptotic effect of ascorbyl stearate in human pancreatic cancer cells: Association with decreased expression of insulin-like growth factor 1 receptor. Dig Dis Sci. 48:230–237. 2003. View Article : Google Scholar : PubMed/NCBI | |
Anthony HM and Schorah CJ: Severe hypovitaminosis C in lung-cancer patients: The utilization of vitamin C in surgical repair and lymphocyte-related host resistance. Br J Cancer. 46:354–367. 1982. View Article : Google Scholar : PubMed/NCBI | |
Maramag C, Menon M, Balaji KC, Reddy PG and Laxmanan S: Effect of vitamin C on prostate cancer cells in vitro: effect on cell number, viability and DNA synthesis. Prostate. 32:188–195. 1997. View Article : Google Scholar : PubMed/NCBI | |
Koh WS, Lee SJ, Lee H, Park C, Park MH, Kim WS, Yoon SS, Park K, Hong SI, Chung MH and Park CH: Differential effects and transport kinetics of ascorbate derivatives in leukemic cell lines. Anticancer Res. 8:2487–2493. 1998. | |
Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Shacter E and Levine M: Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA. 102:13604–13609. 2005. View Article : Google Scholar : PubMed/NCBI | |
Núñez Martín C and Ortiz de Apodaca y Ruiz A: Ascorbic acid in the plasma and blood cells of women with breast cancer. The effect of consumption of food with an elevated content of this vitamin. Nutr Hosp. 10:368–372. 1995.PubMed/NCBI | |
Kurbacher CM, Wagner U, Kolster B, Andreotti PE, Krebs D and Bruckner HW: Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett. 103:183–189. 1996. View Article : Google Scholar : PubMed/NCBI | |
Cooke JP and Dzau VJ: Nitric oxide synthase: Role in the genesis of vascular disease. Annu Rev Med. 48:489–509. 1997. View Article : Google Scholar : PubMed/NCBI | |
Roomi MW, Ivanov V, Netke S, Niedzwiecki A and Rath M: Serum markers of the liver, heart and kidney and lipid profile and histopathology in ODS rats treated with nutrient synergy. J Am Coll Nutr. 22:4772003. |